SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Pastimes : Home on the range where the buffalo roam -- Ignore unavailable to you. Want to Upgrade?


To: allen menglin chen who wrote (2559)6/19/2000 11:12:00 PM
From: Boplicity  Respond to of 13572
 
Subj: THE BULL MARKET REPORT DAILY for MONDAY, JUNE 19, 2000
Date: 6/19/00 5:54:17 PM Central Daylight Time
From: dailybullmkt-owner@listbot.com (The Bull Market Report)
To: gmullineau@aol.com (List Member)

The Bull Market Report - bull-market.com

THE BULL MARKET REPORT DAILY for MONDAY, JUNE 19, 2000
Volume 31, #13

On the Internet, there is no Shortage of Information, but Wisdom is a
Valued Commodity.

To view the newsletter on the web, click here: bull-market.com
We are committed to getting it on the web site by 6:30 PM ET

The Possession of facts is Knowledge.
The Use of them is Wisdom.

MARKET INDICES FROM AROUND THE WORLD
MONDAY, June 19, 2000

INDEX AND CLOSE CHG%: DAY WEEK MO YR

UNITED STATES MARKETS
DOW JONES 10558 109 1.0 1.0 0 -8
THE NASDAQ 3990 129 3.4 3.4 17 -2
THE S&P 500 1486 21 1.5 1.5 5 1

RUSSELL 2000 523 9 1.8 1.8 10 4
G. SACHS INTERNET 473 8 1.8 1.8 14 -34

TREASURY BONDS
10 YEAR 5.99%, up 2 basis points +2bp -30bp -44bp
30 YEAR 5.89%, up 1 basis point +1bp -13bp -60bp

EUROPEAN MARKETS
UK FT-SE 100 6490 -36 -0.6 -0.6 2 -6
FRANCE CAC 40 6505 49 0.8 0.8 1 9
GERMANY DAX 7199 67 1.0 1.0 1 3

ASIAN MARKETS
JAPAN NIKKEI 225 16591 273 1.7 1.7 2 -12
HONGKONG HANGSENG 16267 -167 -1.0 -1.0 11 -4

AMERICAS MARKETS
BRAZIL BOVESPA 16850 425 2.6 2.6 13 -1
CANADA TSE 300 10137 101 1.0 1.0 10 20
MEXICO BOLSA 6551 98 1.5 1.5 10 -8

COMMENTARY

The market rallied sharply on low volume. Do we CARE about low volume?
Not on your life. What we care about was that the Nasdaq was up 3.4% and
the Dow gained back over 40% of what it lost on Friday, despite Honeywell
(HON, $41) losing 8 points, moving the Dow 40 points downwards. Without
the Honeywell move, the Dow would have been up 150 points.

Biotech was on fire today probably because we renamed our Drug and Biotech
newsletter to The Bull Market Biotech Investor. Just kidding. But there
were three double digit returns in our portfolio: Celera (CRA, $120, up
14), Affymetrix (AFFX, $193, up 19) and Human Genome Sciences ($HGSI,
$147, up 13). And except for Pfizer (PFE, $47, down 1), every one of the
stocks in our portfolio was up today. Remember our News Flash on Thursday
last week? We bought Gene Logic (GLGC) at $35 on our buy stop on Friday
and today it closed up 25% today to $45. Wow. Our price target is an
aggressive $60. It seems we are on the right path here and remember, they
have $255 million in cash. "No brainer" comes to mind here. :)

The Financials came back a bit today, with Merrill Lynch (MER, $118, up 4)
the big winner, First Union (FTE, $29) surging 8% higher, and Charles
Schwab adding a point to come within a whisker of $35. Remember Schwabbie
just split their shares 3-2 so this is the equivalent of $52 on the old
shares. The all time high is $44.75 and we could make a strong argument
for the firm to set new highs later this year. After all, are people
canceling their online brokerage accounts lately? We didn't think so.

Internet stocks were strong too led by Inktomi (INKT, $138, up 22, 19%)
and RealNetworks (RNWK, $53, up 7, 15%). Just when you think the game is
over, you see a day like this and realize that this is where you need to
be if you are young and aggressive! Or old and aggressive ,like us! Not
participating was Amazon (AMZN, $45) that saw its shares drop another
point to $45. Wall Street is watching and waiting for profitability . and
selling shares at the same time.

Crude oil is now down below $30 again, so Oil stocks were a bit lower.
We're not concerned until we see crude below $24 a barrel.

Nokia (NOK) set a NEW HIGH today adding another 3 points to close at $61.
Is this a great company or a great company!

MicroStrategy (MSTR, $42, up 4) received $125 million in a private
placement of convertible preferred.

The bull market is back, but really, the bull market never left. Don't
let the doomsdayers do you in. The Internet is exploding; Wireless is
exploding; Biotech is booming, Financials are hot. The bull lives on and
on. Invest now for 2005 and 2010. You and your kids will be sending me
thank you notes!

Good investing.

Todd Shaver
Editor in Chief
The Bull Market Report
Washington, DC

IN THIS ISSUE

1. NORTEL, HP TO OFFER WIRELESS INTERNET
2. LUCENT ACQUIRES HERMANN TECHNOLOGY
3. AOL TO START INTERACTIVE TELEVISION
4. AT&T BUYS WIRELESS SYSTEMS
5. EXCITE@HOME LAUNCHES HIGH SPEED SERVICE IN JAPAN
6. INTEL TO INVEST $2 BILLION IN IRELAND FACILITY
7. YAHOO TO BE ACQUISITIVE IN EUROPE
8. BIOMIRA PRESS RELEASE WE MISSED

=================================================
=================================================

1. NORTEL, HP TO OFFER WIRELESS INTERNET

Nortel Networks (NT, $68, unch.) and Hewlett-Packard (HWP, $118, up 4)
plan to work together to develop mobile portal, wireless, networking and
e-commerce services. The companies said their global strategy is to
deliver ''profitable, seamless, high-speed access to information anytime,
anywhere.'' The new technology is designed to allow users to roam between
networks without losing their Internet connection.

According to Nortel, the global market for wireless infrastructure is
expected to reach $200 billion by 2003.

COMMENT: We'd like to know where Nortel got its numbers from but we don't
disbelieve them. Did you focus on these numbers? Wireless infrastructure
will be a $200 billion business by 2003. That's only three years from
now! As they say, that is HUGE! We want to be invested here.

=================================================
=================================================

2. LUCENT ACQUIRES HERRMANN TECHNOLOGY FOR $440 MILLION

Lucent Technologies (LU, $61, up 1) has acquired Hermann Technology, Inc.,
a leading supplier of devices for next-generation dense wavelength
division multiplexing (DWDM) optical networks. The acquisition
strengthens Lucent's ability to quickly deliver highly integrated,
cost-effective opto-electronic component solutions for the fast-growing
optical networking market. The acquisition will be an all stock
transaction valued at about $438 million.

COMMENT: The big get bigger. The big get more profitable. The big are
the ones we want to own!

=================================================
=================================================

3. AOL TO START INTERACTIVE TELEVISION

America Online Inc.(AOL, $54, down .50) is starting an interactive
television service that will allow TV viewers to chat online and send
e-mail. The service will first be offered in selected markets including
Phoenix, Sacramento, and Baltimore and it will be available through a
set-top box made by Phillips Electronics. The set-top box and wireless
keyboard will only be sold at Circuit City Stores (CC, $35, unch.) and
online through America Online in mid-July. AOLTV will be offered to AOL
members for an additional $14.95 per month, while non-members will pay
$24.95.

COMMENT: This is a big move and one that could be quite lucrative. We
are still watching and waiting. If you are long the stock, we would hold
here, but you could expect to see the stock in the 40's if the overall
market sours. If you don't own any but wish to, set buy stops at say $56
and $58 and $60, in case the stock starts to move.

=================================================
=================================================

4. AT&T BUYS WIRELESS SYSTEMS

AT&T (T, $34, unch.) will spend $3.3 billion to buy wireless systems from
Vodafone AirTouch (VOD, $49, down 1), GTE (GTE, $69, up 3) and PrimeCo
PCS. The deals give AT&T new wireless customers in the San Francisco, San
Diego and Houston markets. AT&T is spending some of the $10.6 billion it
raised from the AT&T Wireless (AWE, $29 , up 1) IPO in April.

The move adds 1.3 million customers to AT&T's wireless customer base and
establishes a foothold in the last three cities in the top 15 U.S. service
markets that do not have AT&T wireless services. In San Francisco, AT&T
is buying the remaining interest in a wireless partnership from Vodafone
AirTouch. In San Diego, it is buying 100 percent of GTE's wireless
operations, while in Houston, it is buying the system owned by PrimeCo.
AT&T Wireless expects about 1,400 employees will join the company as a
result of the transaction.

COMMENT: Great deal for Ma Bell. We're telling you again: The stock at
this price is VERY CHEAP. There is lots of competition and there are lots
of naysayers. We just hope they're short, because when the stock hits
$40, they'll be forced to buy back their shares and force the stock
higher. Don't count AT&T out of this wireless game. We LOVE AT&T
Wireless at this price.

=================================================
=================================================

5. EXCITE@HOME LAUNCHES HIGH SPEED SERVICE IN JAPAN

Excite@Home Corp. (ATHM, $19, unch.) is set to launch its high-speed
Internet service in Japan. The company said its affiliate @Home Japan is
partnering with Jupiter Telecommunications Co. Ltd., the largest Japanese
cable company, and trading company Sumitomo Corp. to roll out the
high-speed service in the Tokyo metropolitan area. In April, the company
said it expects its overseas ventures to record about $80 million in total
revenue this year, an increase of 300 percent over 1999. .

COMMENT: A small deal in the whole scheme of things, but a solid move for
@Home that should bring profits to the bottom line. The company certainly
need some!

=================================================
=================================================

6. INTEL TO INVEST $2 BILLION IN IRISH FACILITY

Continuing it's expansion this year to keep pace with the increasing
demand, Intel Corporation (INTC, $136) will invest $2 billion to expand
manufacturing operations by adding a new wafer fabrication facility at its
European manufacturing operations in Ireland. Much of the expansion this
year, including the addition to the Ireland plant, revolves around Intel's
switch to 12-inch silicon wafers in the manufacturing process. The move
to bigger wafers is critical as it allows the company to be more
efficient. More chips can be placed on bigger wafers, which reduces waste.

COMMENT: Analysts from several firms upped earnings estimates for the
June quarter. The market loved it and the stock rallied big time, jumping
10 points or 8%

=================================================
=================================================

7. YAHOO TO BE ACQUISITIVE IN EUROPE

YAHOO INC (YHOO, $139, down 2) is gearing up for an "aggressive"
acquisition spree in Europe to keep a step ahead of Internet rivals as a
wave of consolidation sweeps the industry, its co-founder said last week.
The recent acquisition of Internet search engine Lycos by Spain's Terra
Networks "reinforces the fact that we all have to look outside the U.S.
for growth and the next big wave," Jerry Yang told Reuters in an
interview. "We will see similar consolidation opportunities in Europe as
we did in the United States and you will see us being very opportunistic
and aggressive," he said, noting Yahoo had made around a dozen purchases
in the United States, from small technology firms to larger Internet
companies.

COMMENT: Yahoo will remain the leader. You heard it here first (a long
time ago!)

=================================================
=================================================

8. BIOMIRA PRESS RELEASE WE MISSED

The following press release was issued by Biomira on May 22nd, and we
never got a chance to focus on it. Now we do.

Biomira Inc. (BIOM, $10,56, up 2%) announced data from a Phase I study of
its BLP25 vaccine for non-small cell lung cancer at the 36th Annual
Meeting of the American Society of Clinical Oncology (ASCO). Martin
Palmer, MD, and colleagues from the Cross Cancer Institute in Edmonton,
Alberta, Canada, reported that the Phase I data shows that BLP25 vaccine
was well tolerated by patients. In addition, in five out of 12 evaluable
patients with Stage IIIb and Stage IV non-small cell lung cancer, BLP25
vaccine elicited a cytotoxic T-Lymphocyte response.

Biomira also released today final survival data on patients from this
Phase I trial treated with either a 20 mg or 200 mg dose of BLP25 vaccine.
The median survival time of patients treated with the 20 mg dose regimen
was 5.5 months from the time of entry to the study. Patients treated with
a 200 mg dose of BLP25 vaccine had a median survival of 14.7 months from
time of entry to the study.

The Company is currently testing patients in a Phase II trial using a
higher dose and frequency protocol of 1000 mg to determine if the new dose
shows improved clinical benefit. This is prior to initiating a trial with
BLP25 vaccine in metastatic non-small cell lung cancer that could
potentially lead to regulatory approvable. The Phase II trial has been
fully enrolled, with six out of eight evaluable non-small cell lung cancer
patients experiencing significant T-cell proliferative responses against
the target antigen.

BLP25 is a 25-amino-acid sequence of the MUC-1 cancer mucin encapsulated
in a liposomal delivery system. Liposomes, or fat droplets smaller than
red blood cells, are believed to enhance recognition of the cancer antigen
by the immune system and facilitate better delivery. The MUC-1 mucin is
an antigen found on the surface of 90% of common cancers.

According to the American Cancer Society, there are approximately 172,000
new cases in the U.S. of non-small cell lung cancer (smoker's cancer) each
year and 160,000 deaths in the U.S., making it the number one cause of
death among all cancers. Biomira estimates the market potential is
represented by the treatment of approximately 100,000 patients each year
in the U.S. alone.

COMMENT: What we missed originally was the fact that they are testing
another drug for cancer and it appears to have lengthened lives in a good
number of cases. Now we know, and think even more highly of the prospects
for the firm. Biomira is still a small cap worth less than $500 million.

=================================================
=================================================

Are you receiving our Investor Series newsletters? They come out weekly
and are free!

The Bull Market Biotech Investor
The Bull Market Wireless Investor
The Bull Market Financial Services Investor
The Internet Investor
The Bull Market Technical Investor - 3 times a week

Visit our subscription page at:
bull-market.com -or- send an email request to
Susan@Bull-Market.com with "Subscribe-Series" in the subject line.

To purchase a GIFT SUBSCRIPTION, click here:
bull-market.com

To REFER A FRIEND, click here: bull-market.com

To CHANGE your email address, click here:
bull-market.com

=================================================
=================================================

~~~ Free! Four chapters of our new book, Ride the Tech Stock
Wave-Safely -- The Option Alternative, delivered by e-mail. Visit
www.800options.com and click Contact to fill out form.
1-800-385-6080.

~~~ For the best book on day trading that we've read, click here:
tradersresource.com. The book comes with a
100% money back guarantee AND a 40% discount.

~~~ For stock split forecasts, covered calls, credit spreads and Leaps:
Go to www.stocksplits.net and www.coveredcall.com. These are simply the
best!

*****&*****&*****&*****&*****&*****&*****&*****&*****&*****
*****&*****&*****&*****&*****&*****&*****&*****&*****&*****

DISCLAIMER

The Bull Market Report, LLC is not a registered Investment Adviser or a
Broker/Dealer. Readers are advised that the report is issued solely for
informational purposes and is not to be construed as an offer to sell or
the solicitation of an offer to buy. The opinions and analyses included
herein are based from sources believed to be reliable and written in good
faith, but no representation or warranty, expressed or implied is made as
to their accuracy, completeness or correctness. Owners, employees and
writers may have positions in the securities that are discussed in the
newsletter.

Readers are urged to consult with their own independent financial advisors
with respect to any investment. All information contained in this report
should be independently verified with the companies mentioned. Please
note that we are taking no compensation of any kind and will never take
any compensation from any companies that we mention in this report.

This is a private e-mail newsletter. No part of the contents of this
e-mail may be copied or forwarded to anyone else (unless you want to
forward one issue to a friend to let them know about us!) Everyone that
receives this newsletter has paid to do so and we would trust that every
subscriber respect this privilege. You may distribute small sections of
The Bull Market Report, as long as it bears the following attribution:
"Source: The Bull Market Report bull-market.com." Thank you
very much.

Copyright The Bull Market Report, LLC, 2000.
All rights reserved



To: allen menglin chen who wrote (2559)6/19/2000 11:13:00 PM
From: Boplicity  Respond to of 13572
 
Subj: THE BULL MARKET DRUG AND BIOTECH INVESTOR for Sunday, June 18, 2000
Date: 6/17/00 11:24:57 PM Central Daylight Time
From: biotech.investor-owner@listbot.com (The Bull Market Drug & Biotech Investor)
To: gmullineau@aol.com (List Member)

The Bull Market Drug & Biotech Investor - bull-market.com

THE BULL MARKET DRUG AND BIOTECH INVESTOR for Sunday, June 18, 2000
THE BULL MARKET BIOTECH INVESTOR (New Name!)
Volume 7, #4
bull-market.com

=================== Sponsor ====================

Get a NextCard Visa, in 30 seconds!

1. Fill in the brief application
2. Receive approval decision within 30 seconds
3. Get rates as low as 2.9% Intro or 9.9% Fixed APR

Apply NOW!
nextcard.com

=================================================

This newsletter is a periodic series of discussions of the changing
Biotech and Pharmaceutical world we live in and the companies that are
going to profit from these changes.

The Bull Market Report web site has links to The Bull Market Drug and
Biotech Investor (http://www.Bull-Market.com). The site includes The Bull
Market Drug and Biotech Portfolio (with 12-month price targets for its 20
stocks), and all issues of The Bull Market Drug and Biotech Investor,
including today's. Descriptions of the companies and links to their web
sites accompany the Portfolio.

We try to cover some of the most relevant news relating to investment
potential in the healthcare industry, and particularly to the companies in
our Portfolio. Just because we haven't mentioned an event or a company
doesn't mean we don't think it's important!

SPECIAL NOTE: We are changing the name of our newsletter. It seems most
of our news is about Biotech so we are going to feature that in the name.
We always thought the old one was too long anyway! We will still cover
the Pharmaceuticals in the newsletter because they are such a powerful
force in the business world and without them we would have very little in
the way of Biotech. So from now on, we are looking at THE BULL MARKET
BIOTECH INVESTOR!

=================================================
=================================================

THANK GENES IT'S FRIDAY

Yes, Friday is back again and so are the Biotech stocks. June 16th was
the third consecutive Friday that the Biotech sector made a good
percentage move. Sure, on Friday, June 2nd, the Nasdaq advanced 6.4% and
the Merrill Lynch Biotech Holders (BBH) advanced 7.2%. Everything "tech"
was up that day. But, on each of the last two Fridays, the Nasdaq has
advanced 1.3% and 0.4% while the Biotech Holders have advanced 4% on each
occasion. Will the trend continue? We don't know but we sure do like it.

Earlier in the week, on Thursday via News Flash, we set a Buy Stop on Gene
Logic (GLGC) at $35. Friday, the stock opened at $34.31 and closed at
$36. We are now long Gene Logic and quite happy about it. See the long
discussion in the Wednesday version of the Biotech Investor. If you have
deleted it or didn't get it, you can always go to the web site.

To provide more information for our readers, we are developing a weekend
edition of The Bull Market Biotech Investor. Our aim is to provide a
recap of some of the week's highlights in the Biotechnology sector as well
as some technical information regarding stocks. Our intent is to give our
readers information to ponder over the weekend -- a time that might be
less hurried in comparison to our busy work week.

The following is a list of last week's best performing Biotech and
Pharmaceutical stocks according to percentage change in price.

Company Symbol Close Change %Chg.

Immunex IMNX $45 10 29
Texas Bio TXB 14 3 25
Celgene CELG 57 9 19
Enzo Bio ENZ 60 9 17
Adv. Tiss ATIS 7 1 14
Avax Tech AVXT 10 1 12
Eli Lilly LLY 85 9 11
Amer Home AHP 58 6 11
MedImmune MEDI 70 6 10
Amgen AMGN 68 5 9
AMBI AMBI 3 0.3 9
Genzyme Tr GZTR 6 0.4 8
Vertex Pharm VRTX 90 7 8
Pharmacia PHA 56 4 8
Biomet BMET 38 3 8
Aviron AVIR 33 2 7
Schrng-Plough SGP 48 3 7
Biogen BGEN 62 4 6
LJL Bio LJLB 19 1 6
Warnr Lambrt WLA 131 7 6
Glaxo Wellcm GLX 56 3 5
Invitrogen IVGN 66 3 5
Qiagen QGENF 176 9 5
Pharm Hldrs PPH 99 5 5
Axys Pharm AXYS 5 0.3 5
IDEC Pharm. IDPH 104 4 4
Pfizer PFE 48 2 4
Geron GERN 27 1 4
Jhnsn & Jhnsn JNJ 90 3 4
Abbott Labs ABT 42 2 4

Shares of Immunex (IMNX) screamed higher this week by 29%. Shares
received a big boost on Friday alone (+19%) due to an upgrade by Bank of
America. They put out a Strong Buy recommendation on Immunex and a $51
price target. In addition to Immunex, other Biotechnology stocks
mentioned by them include: IDEC Pharmaceuticals (IDPH), MedImmune (MEDI),
Gilead Pharmaceuticals (GILD), Amgen (AMGN), Genentech (DNA) and Biogen
(BGEN). Of these stocks, MedImmune, Gilead, Amgen and Genentech are in
our portfolio.

The price move in Immunex shares this past week was in direct contrast to
the price activity of May 26 when the share price dropped to $25 and
change. Immunex released a statement to analysts indicating that its
experimental asthma therapeutic Nuvance did not demonstrate efficacy in
comparison to a placebo. However, Immunex will continue to develop
Nuvance and perform additional phase II trials.

Also effecting the price of Immunex shares lately was a press release
issued on June 6th indicating that the company won permission to market
Enbrel for the treatment of patients in the early stages of rheumatoid
arthritis. The company spokesman indicated that the market for Enbrel
could expand to one million individuals from three hundred thousand. This
news is terrific for the company -- bottom line, increased revenue.

In other news, shares of Geron (GERN) got a quick boost early in the week,
before falling back down a bit, on the news of a collaboration with Celera
Genomics. The goal of this collaboration is to sequence and identify
novel genes that are expressed in stem cells. Stem cells are
undifferentiated, or uncommitted cells that early in embryonic
development, through incompletely defined biochemical mechanisms, change
into nerve cells or liver cells or heart cells or any of the other organs
in our bodies.

The point to consider is that the mature cells in our bodies contain
roughly 100,000 genes and any one cell might express 5-10 % of those
genes. So, genomics studies that examine patterns of gene expression only
capture a small percentage of the genes that a cell can potentially
express. In comparison, a stem cell is likely to express a very different
set of genes than mature cells and the expression of these genes can
provide an indication as to the genetic mechanisms that determine cell
fate. Finally, of significant importance for Geron's goal as a research
company, is to develop regenerative medicine technologies. If Geron can
figure out the genes that influence cell fate, then they can work toward
manufacturing any kind of cell they desire. Of course, this can have many
medical applications from tissue transplantation to drug screening and
toxicology testing.

Robert Mendoza, Ph.D.
Contributing Editor
The Bull Market Drug and Biotech Investor
rmendoza@ucsd.edu

Robert Mendoza has monitored, and made investments in the Biotech sector
since 1985. Dr. Mendoza is currently a research scientist at the
University of California San Diego and is developing models for the gene
therapy of cancer. Robert earned a doctoral degree in Molecular Biology
at the University of California Berkeley and also holds a Master's degree
in Chemistry from the California State University at Fullerton. Of the
companies mentioned in this article, Robert Mendoza holds stock in Immunex.

=================================================
=================================================

2. PORTFOLIO TRACKER

The Bull Market Drug and Biotech Investor Portfolio:
The columns indicate the closing price for stocks on June 9th and June
16th, the change in price and the percentage change. The %YTD represents
the percentage year-to-date change for each security.

Name Symbol 6/9 6/16 Chg. %Chg. %YTD

Affymetrix AFFX 198 174 -24 -12 3
*ALZA AZA 49 50 1 2 2
Amgen AMGN 63 68 5 9 13
Biotech HLDR BBH 160 164 4 3 14
Biomira BIOM 10 10 0 0 150
B-M Squibb BMY 52 53 1 2 -17
*EntreMed ENMD 29 26 -3 -11 -23
Celera Genomics CRA 108 106 -2 -2 -29
*Chiron CHIR 44 43 -1 -2 16
Genentech DNA 134 132 -2 -1 -2

Gilead Sciences GILD 66 66 0 0 21
Human Genome Sci HGSI 140 133 -7 -4 75
Imclone Systems IMCL 88 82 -6 -7 106
*Maxygen MAXY 61 56 -5 -8 -31
MedImmune MEDI 64 70 6 10 27
Millennium MLNM 122 120 -2 -1 97
Merck MRK 70 71 1 2 7
Pfizer PFE 46 48 2 4 48
*Phrmceutcl HLDR PPH 94 99 5 5 9
ViroPharma VPHM 17 15 -2 -9 -59

The portfolio has achieved a year-to-date gain of 10.4%.

*These securities were added to the portfolio after the beginning of the
year. The %YTD return reflects the return since being added to the
portfolio.

Good Biotech investing!

Todd Shaver
Editor in Chief
The Bull Market Report
Washington, DC USA

=================================================
=================================================

Have you tried THE BULL MARKET REPORT DAILY?
Click here for a two-week free trial:
bull-market.com -or- send an email request to
Susan@Bull-Market.com with "FREE TRIAL" in the subject line.

=================================================

SUBSCRIPTION INFORMATION

If you are not a subscriber, click here to subscribe to The Bull Market
Drug and Biotech Investor: bull-market.com

If you like this newsletter, why not subscribe to the entire Investor
Series? They come out weekly and are free!

The Bull Market Drug & Biotech Investor
The Bull Market Wireless Investor
The Bull Market Financial Services Investor
The Internet Investor
The Bull Market Technical Investor

Visit our subscription page at: bull-market.com -or-
send an email request to Susan@Bull-Market.com with "Subscribe-Series" in
the subject line.

To UNSUBSCRIBE from this newsletter, click here:
bull-market.com -or- send an email
request to Susan@Bull-Market.com with "Unsubscribe-Biotech" in the subject
line.

=================================================
=================================================

Disclaimer: Todd Shaver and other contributors to this newsletter may
hold positions in securities mentioned in The Bull Market Drug and Biotech
Investor for purposes of investment or trading.

All information contained in the newsletter is obtained from public
sources. The sources used are believed to be reliable but the accuracy of
this information is not guaranteed.

The Bull Market Report, LLC is not a registered Investment Adviser or a
Broker/Dealer. Readers are advised that the report is issued solely for
informational purposes and is not to be construed as an offer to sell or
the solicitation of an offer to buy. The opinions and analyses included
herein are based from sources believed to be reliable and written in good
faith, but no representation or warranty, expressed or implied is made as
to their accuracy, completeness or correctness. Readers are urged to
consult with their own independent financial advisors with respect to any
investment. All information contained in this report should be
independently verified with the companies mentioned. In addition, The
Bull Market Report is taking no compensation of any kind from any
companies that we mention in this report.

(C) Copyright 2000 The Drug and Biotech Investor and The Bull Market
Report, LLC.